ArticleJournal of managed care & specialty pharmacy2022

Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.

Steven Edelman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.